Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial-Reference-Cited by-同舟云学术

Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial

Published:2021-05-24 Issue:6 Volume:29 Page:1003-1013
ISSN:1930-7381
Container-title:Obesity
language:en
Short-container-title:Obesity

Author:

Whytock Katie L.¹^ORCID,Carnero Elvis A.¹,Vega Rick B.¹,Tillner Joachim²,Bock Christopher¹,Chivukula Karthik¹,Yi Fanchao¹,Meyer Christian¹,Smith Steven R.¹,Sparks Lauren M.¹

Affiliation:

1. Translational Research Institute AdventHealth Orlando Florida USA

2. Translational Medicine Sanofi Frankfurt Germany

Publisher

Wiley

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/oby.23141

Reference36 articles.

1. World Health Organization.Obesity and overweight. Updated April 1 2020. Accessed March 2020.https://www.who.int/en/news‐room/fact‐sheets/detail/obesity‐and‐overweight

2. Obesity;Haslam DW;Lancet,2005

3. Pharmacotherapies for obesity: past, current, and future therapies;Ioannides‐Demos LL;J Obes,2011

4. Anti‐obesity drugs: a review about their effects and safety;Kang JG;Diabetes Metab J,2012

5. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes;Cryer PE;Endocrinology,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease;Cell Metabolism;2024-08

2. New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists;Biomedicines;2024-06-13

3. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity;Endocrine Connections;2024-04-03

4. Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence;Journal of Endocrinology;2024-04-03

5. Dual glucagon‐like peptide‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity;Diabetes, Obesity and Metabolism;2024-04